---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-001246"
form_type: "8-K"
ticker: "ARDX"
cik: "0001437402"
company_name: "ARDELYX, INC."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:04:51.712547+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Ardelyx reports preliminary Q4 2024 net product sales: IBSRELA $54M, XPHOZAH $57M

## Summary
- IBSRELA net product sales: ~$54M in Q4 2024, ~$158M full year.
- XPHOZAH net product sales: ~$57M in Q4 2024, ~$161M full year.
- Cash, cash equivalents, and short-term investments: ~$250M as of Dec 31, 2024 (unaudited).

## SEC filing metadata
- accession: 0001628280-25-001246
- form_type: 8-K
- ticker: ARDX
- cik: 0001437402
- company_name: ARDELYX, INC.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1437402/000162828025001246/0001628280-25-001246-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1437402/000162828025001246/ardx-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-001246
- JSON: https://secwatch.observer/filing/0001628280-25-001246.json
- Plain text: https://secwatch.observer/filing/0001628280-25-001246.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.